Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...
The function allows users to engage in an interactive video conversation with the AI technology behind the chatbot, according to an announcement last Friday via Doubao’s WeChat account. Users can ...
Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning. We're going to go ahead and get started. Perfect. So, of ...
Recursion Pharmaceuticals Inc. (RXRX) reported its Q1 2025 financial results, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.5 against ...
Read Recursion Pharmaceuticals, Inc. (RXRX) Q1 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...
Recursion Pharmaceuticals (NASDAQ: RXRX), a $3.03 billion market cap biotech company, reported a larger-than-expected loss for Q4 2024, with an EPS of -0.53 compared to the forecasted -0.41. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results